Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EHP-101 (Primary)
  • Indications Multiple sclerosis; Systemic scleroderma
  • Focus Adverse reactions; First in man
  • Sponsors Emerald Health Pharmaceuticals
  • Most Recent Events

    • 26 Aug 2019 According to an Emerald Health Pharmaceuticals Media release, the company plans to announce top-line results from this study before end of 2019, once the data are fully analyzed, and will be submitting the study results for presentation at upcoming international conferences.
    • 26 Aug 2019 According to an Emerald Health Pharmaceuticals Media release, the safety and tolerability profile of EHP-101 from this study will define an appropriate dosing regimen and proceed with the planned Phase II studies in multiple sclerosis and systemic scleroderma patients.
    • 26 Aug 2019 Results published in the Emerald Health Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top